Explanation of gastric indigestion in- Iranian traditional medicine and effect assessment of Zabib syrup on gastric indigestion due to stomach cold and wet dystemperament

Effect assessment of Zabib syrup on gastric indigestion due to stomach cold and wet dystemperament

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016081129301N1

Enrollment

Registered

2016-09-14

Start date

2016-09-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional dyspepsia. Indigestion

Interventions

Intervention 1: In the study group, syrup Zabib approved by the Ministry of Health with registration number 92-0229-Q, at a rate of 10 cc after each meal for a four-week period will be taken. Interven

Treatment - Drugs

In the study group, syrup Zabib approved by the Ministry of Health with registration number 92-0229-Q, at a rate of 10 cc after each meal for a four-week period will be taken.

In the control group a dose of 40 mg omeprazole (20 mg in the morning, 20 mg at night) for a four-week period will be taken.

Eligibility

Sex/Gender

All

Age

14 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients aged 14 to 65 years old; patients with symptoms of functional dyspepsia. Exclusion criteria: dyspepsia due to causes such as peptic ulcer, gastritis, cancer or known cause; hot stomach dystemperament; dry stomach dystemperament; patients who are taking medications with possible effects on digestion and pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Symptoms of dyspepsia. Timepoint: Baseline and 4th week after intervention. Method of measurement: The Gastrointestinal Symptom Scale.	—

Secondary

Measure	Time frame
Postprandial fullness. Timepoint: At baseline,4 weeks after starting the intervention. Method of measurement: The Gastrointestinal Symptom Scale.;Early Satiety. Timepoint: At baseline,4 weeks after starting the intervention. Method of measurement: The Gastrointestinal Symptom Scale.;Bloating. Timepoint: At baseline,4 weeks after starting the intervention. Method of measurement: The Gastrointestinal Symptom Scale.;Nausea. Timepoint: At baseline,4 weeks after starting the intervention. Method of measurement: The Gastrointestinal Symptom Scale.;Anorexia. Timepoint: At baseline,4 weeks after starting the intervention. Method of measurement: The Gastrointestinal Symptom Scale.	—

Measure

Time frame

Postprandial fullness. Timepoint: At baseline,4 weeks after starting the intervention. Method of measurement: The Gastrointestinal Symptom Scale.;Early Satiety. Timepoint: At baseline,4 weeks after starting the intervention. Method of measurement: The Gastrointestinal Symptom Scale.;Bloating. Timepoint: At baseline,4 weeks after starting the intervention. Method of measurement: The Gastrointestinal Symptom Scale.;Nausea. Timepoint: At baseline,4 weeks after starting the intervention. Method of measurement: The Gastrointestinal Symptom Scale.;Anorexia. Timepoint: At baseline,4 weeks after starting the intervention. Method of measurement: The Gastrointestinal Symptom Scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Hoseinzadeh

Mashhad University of Medical Sciences, Faculty of Traditional and Complementary Medicine

Hoseinzadehh1@mums.ac.ir+98 51 3855 2188

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026